BRPI0911577B8 - derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica - Google Patents

derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica

Info

Publication number
BRPI0911577B8
BRPI0911577B8 BRPI0911577A BRPI0911577A BRPI0911577B8 BR PI0911577 B8 BRPI0911577 B8 BR PI0911577B8 BR PI0911577 A BRPI0911577 A BR PI0911577A BR PI0911577 A BRPI0911577 A BR PI0911577A BR PI0911577 B8 BRPI0911577 B8 BR PI0911577B8
Authority
BR
Brazil
Prior art keywords
treatment
spiro
indole derivatives
parasitic diseases
plasmodium
Prior art date
Application number
BRPI0911577A
Other languages
English (en)
Inventor
Zou Bin
Ks Yeung Bryan
Jocelyn Tan Liying
Krastel Philipp
Yong Leong Seh
Hua Ang Shi
Lin Josephine Wong Wei
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911577(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0911577A2 publication Critical patent/BRPI0911577A2/pt
Publication of BRPI0911577A8 publication Critical patent/BRPI0911577A8/pt
Publication of BRPI0911577B1 publication Critical patent/BRPI0911577B1/pt
Publication of BRPI0911577B8 publication Critical patent/BRPI0911577B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

derivados espiro-indol para o tratamento de doenças parasíticas. a presente invenção refere-se a compostos orgânicos que têm propriedades farmacêuticas interessantes. em particular, os compostos são úteis no tratamento e/ou prevenção de infecções tais como aquelas causadas por plasmodium falciparum, plasmodium vivax, plasmodium malariae, plasmodium ovale, trypanosoma cruzzi e parasitas do gênero leishmania tal como, por exemplo, leishmania donovani. a invenção também se refere a composições farmacêuticas contendo os compostos, bem como processos para sua preparação.
BRPI0911577A 2008-04-29 2009-04-01 derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica BRPI0911577B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08155342 2008-04-29
EP08155342.2 2008-04-29
EP09151117.0 2009-01-22
EP09151117 2009-01-22
PCT/EP2009/053902 WO2009132921A1 (en) 2008-04-29 2009-04-01 Spiro-indole derivatives for the treatment of parasitic diseases

Publications (4)

Publication Number Publication Date
BRPI0911577A2 BRPI0911577A2 (pt) 2016-01-05
BRPI0911577A8 BRPI0911577A8 (pt) 2018-03-06
BRPI0911577B1 BRPI0911577B1 (pt) 2021-02-23
BRPI0911577B8 true BRPI0911577B8 (pt) 2021-05-25

Family

ID=40613087

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911577A BRPI0911577B8 (pt) 2008-04-29 2009-04-01 derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica

Country Status (30)

Country Link
US (2) US8053442B2 (pt)
EP (2) EP2285808B1 (pt)
JP (2) JP5438098B2 (pt)
KR (1) KR101390081B1 (pt)
CN (1) CN102015711B (pt)
AR (1) AR071222A1 (pt)
AU (1) AU2009242279B2 (pt)
BR (1) BRPI0911577B8 (pt)
CA (1) CA2719365C (pt)
CL (1) CL2009001007A1 (pt)
CO (1) CO6300940A2 (pt)
CY (1) CY1114874T1 (pt)
DK (1) DK2285808T3 (pt)
EA (1) EA019601B1 (pt)
EC (2) ECSP10010646A (pt)
ES (1) ES2447590T3 (pt)
HR (1) HRP20140151T1 (pt)
IL (1) IL208357A (pt)
JO (1) JO2904B1 (pt)
MA (1) MA32316B1 (pt)
MX (1) MX2010011868A (pt)
MY (2) MY156601A (pt)
NZ (1) NZ588217A (pt)
PE (1) PE20091787A1 (pt)
PL (1) PL2285808T3 (pt)
PT (1) PT2285808E (pt)
SI (1) SI2285808T1 (pt)
TW (1) TWI442921B (pt)
WO (1) WO2009132921A1 (pt)
ZA (1) ZA201006752B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases
CN102584835B (zh) * 2011-01-17 2014-08-27 苏州大学 一种含吲哚结构的螺杂环化合物及其制备方法
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP3578557B1 (en) * 2012-03-23 2023-09-20 Novartis AG Chemical process for preparing spiroindolones and intermediates thereof
CN106232619B (zh) 2013-11-13 2022-09-09 科德克希思公司 工程化的亚胺还原酶和用于酮和胺化合物的还原胺化的方法
CN107002050A (zh) 2014-11-25 2017-08-01 科德克希思公司 工程化亚胺还原酶和用于酮和胺化合物的还原胺化的方法
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
ES2754803T3 (es) * 2015-01-23 2020-04-20 Glaxosmithkline Ip Dev Ltd Derivado de pirazolo[3,4-dpirimidina y su uso para el tratamiento de leishmaniasis
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
JP2017024992A (ja) * 2015-07-15 2017-02-02 公益財団法人微生物化学研究会 化合物の製造方法
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CN110590795B (zh) * 2019-10-10 2021-01-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一类多并杂环螺羟吲哚类化合物的合成方法
US20230132973A1 (en) * 2020-03-17 2023-05-04 The University Of Buea DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
CN116273188B (zh) * 2023-03-01 2024-06-25 岭南师范学院 一种负载金属的多孔有机框架材料在催化Pictet-Spengler反应中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NZ509324A (en) * 1998-07-14 2003-07-25 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
BR9916371A (pt) 1998-12-19 2001-09-18 Janssen Pharmaceutica Nv Composto de espiro anti-histamìnico
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases

Also Published As

Publication number Publication date
CN102015711A (zh) 2011-04-13
MA32316B1 (fr) 2011-05-02
WO2009132921A1 (en) 2009-11-05
MX2010011868A (es) 2010-11-26
PT2285808E (pt) 2014-02-24
EP2285808A1 (en) 2011-02-23
JP2011518852A (ja) 2011-06-30
NZ588217A (en) 2012-10-26
HRP20140151T1 (hr) 2014-03-28
AU2009242279B2 (en) 2012-08-30
CA2719365A1 (en) 2009-11-05
PL2285808T3 (pl) 2014-04-30
TW200948357A (en) 2009-12-01
IL208357A (en) 2014-11-30
DK2285808T3 (da) 2014-02-03
CL2009001007A1 (es) 2010-06-11
JP5438098B2 (ja) 2014-03-12
BRPI0911577A8 (pt) 2018-03-06
EP2722333A1 (en) 2014-04-23
US20090275560A1 (en) 2009-11-05
EA019601B1 (ru) 2014-04-30
JP2014065729A (ja) 2014-04-17
AR071222A1 (es) 2010-06-02
ES2447590T3 (es) 2014-03-12
BRPI0911577B1 (pt) 2021-02-23
ZA201006752B (en) 2011-05-25
KR20100135320A (ko) 2010-12-24
PE20091787A1 (es) 2009-12-14
MY156601A (en) 2016-03-15
CO6300940A2 (es) 2011-07-21
SI2285808T1 (sl) 2014-03-31
HK1149935A1 (en) 2011-10-21
AU2009242279A1 (en) 2009-11-05
US8399453B2 (en) 2013-03-19
KR101390081B1 (ko) 2014-04-29
TWI442921B (zh) 2014-07-01
CN102015711B (zh) 2013-05-01
ECSP17068127A (es) 2017-10-31
BRPI0911577A2 (pt) 2016-01-05
CA2719365C (en) 2017-03-07
JO2904B1 (en) 2015-09-15
EA201001689A1 (ru) 2011-08-30
US8053442B2 (en) 2011-11-08
MY152021A (en) 2014-08-15
ECSP10010646A (es) 2010-12-30
IL208357A0 (en) 2010-12-30
CY1114874T1 (el) 2016-12-14
US20110275613A1 (en) 2011-11-10
EP2285808B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
ECSP17068127A (es) Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
UA108219C2 (uk) Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти)
BR112012012947B8 (pt) sal de hemitartarato e composição farmacêutica compreendendo o mesmo
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BRPI0916456A2 (pt) composto e composição lipídicos e respectivos métodos de produção e usos (incluindo método de tratamento e de prevenção de doenças que utilizam os mesmos)
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
BR112013005622A2 (pt) heteroaril metil amidas
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
WO2010057101A3 (en) Compounds useful as hiv blockers
JO3416B1 (ar) تركيبات مضادة للبكتيريا وطرق استخدامها
BR112012011328A2 (pt) inibidores de akt
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
BRPI0818618B8 (pt) composto antimalárico, e, composição farmacêutica
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
WO2010095042A3 (en) Pyridocarbazole type compounds and applications thereof
CO6321288A2 (es) Sales de compuestos inhibidores de vih
BR112014032964A2 (pt) composto, composição farmacêutica, uso do composto, e, método para preparar o composto
UA107088C2 (xx) 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
BR112014004437A8 (pt) composto, composição farmacêutica, preparação farmacêutica, processo para o preparo de um composto de fórmula, intermediário, métodos para a prevenção ou tratamento de malária e para inativação de infecção parasítica em uma célula.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF